Valuation: Genovis AB

Market Cap 1.35B 137M 120M 113M 103M 192M 13.14B 193M 520M 6.69B 515M 504M 21.6B P/E 2026 *
63.5x
P/E 2027 * 40x
Enterprise Value 1.24B 126M 110M 103M 94.15M 177M 12.06B 177M 477M 6.14B 473M 462M 19.83B EV / Sales 2026 *
8.41x
EV / Sales 2027 * 6.49x
Free-Float
92.6%
Yield 2026 *
-
Yield 2027 * -
1 day-0.40%
1 week-0.90%
Current month-10.07%
1 month-0.90%
3 months+9.57%
6 months+21.02%
Current year-6.26%
1 week 19.6
Extreme 19.6
20.5
1 month 19.6
Extreme 19.6
22.8
Current year 15.64
Extreme 15.64
23.65
1 year 15.64
Extreme 15.64
24.5
3 years 15.64
Extreme 15.64
53.9
5 years 15.64
Extreme 15.64
90
10 years 2.12
Extreme 2.12
90
Manager TitleAgeSince
Chief Executive Officer 55 05/05/2015
Director of Finance/CFO 42 01/08/2026
Chief Tech/Sci/R&D Officer 42 01/01/2017
Director TitleAgeSince
Director/Board Member 77 01/01/2014
Director/Board Member 65 01/01/2019
Chairman 74 05/05/2020
Date Insider Type Main position Quantity % Market Cap. Importance
5/15/26 A Buy 4,146 0.0063%
2/24/26 A Buy

Chief Financial Officer

3,137 0.0047%
2/24/26 A Buy

Chief Financial Officer

2,470 0.0037%
Change 5-day change 1-year change 3-year change Capi.($)
-0.40%-0.90%-12.25%-59.22% 137M
-2.70%+4.23%+192.64%+570.01% 24.07B
+2.98%+12.88%+506.90%+88.83% 9.98B
+0.98%+1.05%-36.63%-19.81% 9.66B
+1.33%+16.74%-7.68% - 8.47B
-0.18%+0.18%+100.56%+66.75% 6.56B
+0.22%+1.81%-27.93%-22.57% 5.74B
+1.77%+5.52%-0.26%-10.66% 4.35B
+2.67%+3.88%+65.15%+74.36% 3.89B
+1.09%+4.43%-19.18%-31.46% 2.74B
Average +0.80%+6.34%+76.13%+72.91% 7.56B
Weighted average by Cap. +0.15%+9.57%+131.93%+221.55%

Financials

2026 *2027 *
Net sales 147M 14.97M 13.05M 12.3M 11.2M 20.99M 1.43B 21.02M 56.75M 731M 56.24M 55M 2.36B 185M 18.86M 16.44M 15.49M 14.1M 26.44M 1.81B 26.47M 71.48M 920M 70.83M 69.26M 2.97B
Net income 15.7M 1.6M 1.39M 1.31M 1.19M 2.24M 153M 2.24M 6.05M 77.91M 6M 5.86M 251M 33.6M 3.42M 2.98M 2.81M 2.56M 4.79M 327M 4.8M 12.95M 167M 12.83M 12.55M 538M
Net Debt -111M -11.29M -9.84M -9.27M -8.44M -15.83M -1.08B -15.85M -42.78M -551M -42.4M -41.46M -1.78B -145M -14.74M -12.86M -12.11M -11.03M -20.67M -1.41B -20.7M -55.89M -720M -55.38M -54.16M -2.32B
Logo Genovis AB
Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.
Employees
42
Date Price Change Volume
21/09/26 SEK 19.92 -0.40% 40,743
18/09/26 SEK 20.00 -1.48% 25,353
17/09/26 SEK 20.30 -0.25% 28,429
16/09/26 SEK 20.35 +0.25% 152,118
15/09/26 SEK 20.30 +1.00% 44,581
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
20.00SEK
Average target price
33.00SEK
Spread / Average Target
+65.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GENO Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!